Provided by
Dow Jones
By Jared S. Hopkins and Matt Grossman
Pfizer Inc. said it expects its Covid-19 vaccine to generate about $15 billion in sales this year, indicating the business opportunity created by protecting people from the pandemic.
The vaccine contributed $154 million of the company's $11.7 billion in sales during the fourth quarter, helping lift the company's overall revenue from all vaccines to $2 billion, a 17% year-over-year increase.
Pfizer projects the vaccine's impact will be considerable this year, becoming one of the company's top-selling products. In 2021, Pfizer expects full-year revenue of between $59.4 billion and $61.4 billion, and adjusted earnings of between $3.10 and $3.20 a share.